ARTICLE | Clinical News

Ciliary neurotrophic factor data

September 13, 1993 7:00 AM UTC

REGN reported at the World Congress of Neurology in Vancouver, Canada, on its Phase II trial results. The highest of the six doses of CNTF tested, 30 µg/kg, slowed the rate of deterioration in muscle strength, although the difference was not statistically significant. For each of the three measures in the study, the statistical probability that effects were due to CNTF ranged from 80 to 92 percent.

In 12 patients given the 30 µg/kg dose, the rate of deterioration of muscle function was slowed by 72 percent, and the decline in lung function was cut by between 44 percent to 69 percent, compared to 14 patients given placebo. ...